Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone

• Published in: Journal of clinical microbiology 2018-08, Vol.56 (8)
• Main Authors: Pfaller, M A, Flamm, R K, McCurdy, S P, Pillar, C M, Shortridge, D, Jones, R N
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Bacteriology; Enterobacteriaceae - drug effects; Fluoroquinolones - pharmacology; Humans; Microbial Sensitivity Tests - standards; Microbial Viability - drug effects; Quality Control; Staphylococcus - drug effects
• ISSN: 0095-1137; 1098-660X
• DOI: 10.1128/JCM.00339-18

Delafloxacin, a recently approved anionic fluoroquinolone, was tested within an international resistance surveillance program. The susceptibilities of 7,914 indicated pathogens causing acute bacterial skin and skin structure infections (ABSSSI) were determined using Clinical and Laboratory Standards Institute (CLSI) broth microdilution MIC testing methods. The U.S. Food and Drug Administration (FDA) susceptibility testing breakpoints and quality control ranges for routine broth microdilution and disk diffusion methods were confirmed. The delafloxacin MIC (% susceptibility) results were as follows: , including methicillin-resistant (MRSA), 0.008/0.25 μg/ml (92.8%); , 0.016/0.03 μg/ml (99.3%); , 0.016/0.03 μg/ml (100.0%); group, 0.008/0.016 μg/ml (100.0%); , 0.12/1 μg/ml (66.2%); and , 0.12/4 μg/ml (69.5%). The FDA clinical breakpoints were used to assess intermethod test agreement between delafloxacin MIC and disk diffusion methods for the indicated pathogens. The intermethod susceptibility test categorical agreement for delafloxacin was acceptable, with only 0.4% very major, false-susceptible errors among strains. Across all FDA-indicated species, the selected breakpoints produced only 0.0 to 1.7% rates of serious (very major and major errors) intermethod error. Quality control ranges for these standardized delafloxacin susceptibility test methods were calculated from three multilaboratory (12 total sites) studies for six control organisms. In conclusion, the application of FDA MIC breakpoints for delafloxacin against contemporary (2014 to 2016) isolates of ABSSSI pathogens provides additional support for the use of delafloxacin in the treatment of adults with ABSSSI. Delafloxacin MIC and disk diffusion susceptibility testing methods have been standardized for clinical application, achieving high intermethod categorical agreement.